Comparing glycaemic benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR):Study protocol for a randomised controlled trial by Wilcox, Joanne et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s13063-016-1543-6
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Wilcox, J., Waite, C., Tomlinson, L., Driscoll, J., Karim, A., Day, E., & Sharif, A. (2016). Comparing glycaemic
benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR): Study protocol
for a randomised controlled trial. Trials, 17(1), [417]. 10.1186/s13063-016-1543-6
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
STUDY PROTOCOL Open Access
Comparing glycaemic benefits of Active
Versus passive lifestyle Intervention in
kidney Allograft Recipients (CAVIAR): study
protocol for a randomised controlled trial
Joanne Wilcox1, Chantelle Waite1, Lyndsey Tomlinson2, Joanne Driscoll2, Asra Karim1, Edward Day3
and Adnan Sharif1,4*
Abstract
Background: Lifestyle modification is widely recommended to kidney allograft recipients post transplantation due
to the cardiometabolic risks associated with immunosuppression including new-onset diabetes, weight gain and
cardiovascular events. However, we have no actual evidence that undertaking lifestyle modification protects from
any adverse outcomes post transplantation. The aim of this study is to compare whether a more proactive versus
passive interventional approach to modify lifestyle is associated with superior outcomes post kidney transplantation.
Methods/design: We designed this prospective, single-centre, open-label, randomised controlled study to compare
the efficacy of active versus passive lifestyle intervention for kidney allograft recipients early post transplantation.
A total of 130 eligible patients, who are stable, nondiabetic and between 3 and 24 months post kidney
transplantation, will be recruited. Randomisation is being undertaken by random block permutations into passive
(n = 65, leaflet guidance only) versus active lifestyle modification (n = 65, supervised intervention) over a 6-month
period. Supervised intervention is being facilitated by two dietitians during the 6-month intervention period to
provide continuous lifestyle intervention guidance, support and encouragement. Both dietitians are accredited
with behavioural intervention skills and will utilise motivational aids to support study recruits randomised to active
intervention. The primary outcome is change in abnormal glucose metabolism parameters after 6 months of
comparing active versus passive lifestyle intervention. Secondary outcomes include changes in a wide array of
cardiometabolic parameters, kidney allograft function and patient-reported outcome measures. Long-term tracking
of patients via data linkage to electronic patient records and national registries will facilitate long-term comparison
of outcomes after active versus passive lifestyle intervention beyond the 6-month intervention period.
Discussion: This is the first randomised controlled study to investigate the benefits of active versus passive lifestyle
intervention in kidney allograft recipients for the prevention of abnormal cardiometabolic outcomes. In addition,
this is the first example of utilising behaviour therapy intervention post kidney transplantation to achieve clinically
beneficial outcomes, which has potential implications on many spheres of post-transplant care.
Trial registration: This study was registered with the Clinical Trials Registry on 27 August 2014 (ClinicalTrials.org
Identifier: NCT02233491).
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Background
Post-transplantation diabetes mellitus (PTDM) is a com-
mon medical complication after kidney transplantation
and is associated with long-term morbidity, mortality
and increased cost [1]. From a patient perspective, devel-
opment of PTDM is cited by kidney transplant recipi-
ents as their biggest concern post transplantation after
the risk of graft loss, death and cancer [2]. In the imme-
diate postoperative setting over 85 % of kidney allograft
recipients have evidence of significant hyperglycaemia
[3] and it has been estimated that, using contemporary
diagnostic criteria, up to 39 % of kidney allograft recipients
will develop PTDM within the first year after transplant-
ation [1]. PTDM is common because kidney transplant
recipients have both transplant-specific (e.g. immunosup-
pression) and nonspecific (e.g. age, ethnicity, obesity) risk
factors [4]. Therefore, strategies to attenuate this high risk
for developing PTDM (and other cardiometabolic risk
factors such as weight gain, hyperlipidaemia and hyperten-
sion) should be actively pursued after kidney transplant-
ation to prevent adverse long-term outcomes, although
evidence that providing this advice improves clinical out-
comes is lacking.
In the general population, lifestyle modification has
been shown to reduce the long-term risk of developing
type-2 diabetes mellitus among high-risk patients (e.g.
those with pre-diabetes). Tuomilehto et al. showed how
the cumulative incidence of diabetes in a lifestyle inter-
vention group was 11 % compared with 23 % in a con-
trol group of similar characteristics, resulting in a 58 %
reduction in the risk of diabetes (hazard ratio 0.4, 95 %
confidence interval 0.3–0.7, p < 0.001) [5]. In another
study to support these findings, Pan et al. showed that
diet, exercise and a diet-plus-exercise intervention was
associated with a relative risk of 0.69 (standard error
0.17, p < 0.03), 0.54 (standard error 0.01, p < 0.0005)
and 0.58 (standard error 0.17, p < 0.005), respectively,
in the risk of developing diabetes compared with the
control group [6]. Finally, Lindstrom et al. demonstrated
a reduced hazard ratio of 0.57 (95 % confidence
interval 0.43–0.76, p = 0.00001) secondary to lifestyle
intervention [7]. Importantly, in this latter study the
beneficial changes persisted after discontinuation of the
intervention. Recent data has confirmed that lifestyle
intervention is associated with a reduced hazard ratio of
0.73 (95 % confidence interval 0.65–0.83, p < 0.0001) in
diabetes incidence during a mean follow-up of 15 years
after participation in the 3-year Diabetes Prevention
Programme [8], attenuating concern regarding long-term
sustainability beyond interventional study periods.
While evidence to support lifestyle modification exists
in the general population, it is important to appreciate
the different pathophysiology associated with the devel-
opment of type-2 diabetes mellitus versus PTDM. In a
multicentre collaboration, Hecking et al. analysed gly-
caemic parameters comparing kidney allograft recipients
with individuals from the general population (both nor-
mal subjects and those with type-2 diabetes mellitus),
demonstrating disparate pathophysiology favouring more
pancreatic beta-cell dysfunction in the transplant cohort
with PTDM [9]. Despite these differences, clinical evi-
dence from the general population is frequently extrapo-
lated to kidney allograft recipients and current guidance
recommending lifestyle modification for all kidney allo-
graft recipients to attenuate their risk for PTDM is one
example of this [10]. However, there is a growing consen-
sus on the urgent need for transplant-specific clinical
studies due to altered risk factor patterns and reverse epi-
demiology being commonly described in the renal failure
population [11].
We have previously demonstrated the successful use
of active lifestyle modification in the setting of kidney
transplantation [12]. Kidney allograft recipients with
abnormal postprandial glucose metabolism on an oral
glucose tolerance test (OGTT) (impaired glucose toler-
ance and PTDM, n = 36) were selected to have active
lifestyle modifications (dietitian referral, a graded exer-
cise programme and weight-loss advice), while kidney
allograft recipients with normal postprandial glucose
metabolism (normal and impaired fasting glucose, n = 79)
received leaflets advocating healthy lifestyle modifications
alone. In this study, patients receiving active lifestyle
intervention demonstrated a significant reduction in
postprandial glucose levels (10.2 mmol/L to 8.7 mmol/L,
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Δ = −15 %, p = 0.012) and improved reclassification of gly-
caemic status on reevaluation by OGTT 6 months later.
By contrast, simple lifestyle modification advice by leaflets
alone in the group with normal glucose tolerance resulted
in a significant deterioration of postprandial glucose levels
(5.9 mmol/L to 6.6 mmol/L, Δ = +12 %, p = 0.001) and
worse glycaemic status reclassification on follow-up
OGTT. The limitations of this study were the lack of ran-
domisation and noncomparable groups (with different
metabolic profiles), meaning that a direct comparison of
the benefits of active versus passive lifestyle intervention
was not possible. Therefore, it is difficult to ascertain
whether changes in glucose metabolism were directly
linked to active versus passive lifestyle intervention.
To fill this gap in the literature, and to determine
transplant-specific clinical evidence, this study has been
designed as the first randomised controlled trial to as-
sess the efficacy of active versus passive lifestyle inter-
vention in a high-risk transplant cohort to attenuate the
risk of abnormal glucose metabolism. In addition to
being the first clinical trial of lifestyle intervention, this
randomised controlled trial is also the first example of a
behaviour change protocol being utilised as part of an
interventional programme to alter behaviour post trans-
plantation, which could have potential applications
beyond lifestyle intervention alone for solid organ trans-
plant recipients. Interventions to change health-related
behaviours, such as diet and exercise, are usually com-
plex, consisting of many interacting components [13].
Furthermore, they are often poorly reported in the
research literature, limiting the possibility of identifying
their effective ingredients. Therefore, attention has re-
cently been paid to the standardised reporting of inter-
vention content and the component behaviour change
techniques (BCTs) [13, 14]. The development of a tax-
onomy of BCTs has allowed the use of meta-analysis
and meta-regression to assess the effectiveness of behav-
iour change interventions designed to promote physical
activity and healthy eating [15–17]. This work suggests
that self-regulatory techniques congruent with Control
Theory [18] are significantly more effective than inter-
ventions not including these techniques. These include
encouraging the individual to decide to act (intention
formation), prompting specific goal setting, providing
feedback on performance and self-monitoring of behav-
iour, and reviewing previously set goals or intentions.
These techniques were combined with two other effect-
ive strategies to support the behaviour change inter-
vention. Firstly, ‘Node-link mapping’ (NLM) is a simple
visual representation system for presenting behaviour
change interventions, supported by a body of educa-
tional psychology and treatment research showing that
its use is more effective than standard consultation tech-
niques for improving the therapeutic alliance, increasing
focus on key issues during the session, and improving
outcomes [19]. It also has an evidence base in patients
with poor reading skills or working in a language other
than their first language [19]. Secondly, Social Behaviour
and Network Therapy (SBNT) focusses on building so-
cial network support for behaviour change by assessing
the patient’s level of support from family and friends and
inviting key supportive others to assist with goal setting
and monitoring. Evidence supporting the validity of this
intervention has been published in the liver transplant
population [20] and will be translated over to a kidney
transplant cohort.
In summary, this randomised controlled trial will
assess the efficacy of a novel behaviour change interven-
tion technique to encourage active lifestyle modification
in nondiabetic kidney allografts recipients who are at
risk for PTDM and promises to fill an important gap in
the literature to guide clinical management and patient
counselling.
Specific research questions
This study is designed to answer four important questions
relevant to kidney transplant recipients who are at risk of
developing PTDM:
1. Does lifestyle modification intervention improve
glycaemic, cardiometabolic, clinical and
physiological parameters in kidney allograft
recipients?
2. Is active dietitian-led intervention (incorporating a
behaviour therapy approach) more effective than
passive leaflet-driven guidance?
3. Does active versus passive lifestyle modification
improve patient-reported outcomes measures post
kidney transplantation?
4. Are there long-term clinical advantages beyond the
6-month intervention period for either active or
passive groups?
Methods/design
Study design
This is a prospective, single-centre, open-label, rando-
mised controlled study comparing active versus passive
lifestyle intervention post kidney transplantation. All eli-
gible kidney allograft recipients who meet the inclusion/
exclusion criteria will be invited to participate. The
duration of the clinical intervention in the study will be
6 months, with electronic data-linkage follow-up extending
out to 5 years post study participation.
Study setting
Patients will be recruited from a single transplant centre lo-
cated in Birmingham, England, and it is planned to recruit
130 nondiabetic kidney allograft recipients. Birmingham,
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and the greater West Midlands region which it serves,
contains a diverse multicultural population and this study is
keen to ensure that study participation is representative of
the population we serve. Therefore, we will strive to ensure
adequate representation from the Black, Asian and Minor-
ity Ethnic (BAME) communities. Our dietitians have excel-
lent experience of working with the local demographics in
Birmingham and tailored information for the various
BAME cohorts will be available via both the active and
passive lifestyle intervention arms.
Inclusion and exclusion criteria
Inclusion criteria
 Aged 18 and over
 Kidney allograft only
 Functioning allograft (not on dialysis)
 Between 3 and 24 months post kidney
transplantation
Exclusion criteria
 Multiorgan transplant recipient
 Preexisting known diabetes
 Pregnancy
 Physically unable to undertake exercise assessments
Study protocol and interventions
Potential participants will be identified through compu-
terised search of medical records on patients attending
clinic and from clinicians in charge of outpatient services.
Relevant clinic lists will be reviewed on a weekly basis and
potential participants identified (first approach will be
from medical team or renal research nurse). Potential par-
ticipants will be given the opportunity to reflect on the
information given both verbally and within the written in-
formation sheet. No fixed time is specified for the length
or timing of this prior interview as it will be dependent
upon the patient’s understanding of their underlying dis-
ease, transplantation and complications, as well as their
understanding of the research project.
Kidney allograft recipients who fulfil the eligibility cri-
teria and give informed consent will be subsequently
randomised into active versus passive intervention arms
(at which point an OGTT is performed in each patient
after randomisation and before intervention) (see Fig. 1).
Randomisation will be facilitated through www.sealeden
velope.com, using random permuted blocks within strata
to balance numbers and characteristics, into one of the
following lifestyle intervention groups (n = 65 for each
intervention group, total 130 participants):
Active intervention group. This group will receive active
lifestyle modification intervention and will consist
of dietitian referral, a graded exercise programme
and weight-loss advice. Each patient will have four
face-to-face appointments with the dietitian (lasting
45–60 min) at baseline, day 30, day 60 and day 120.
Brief telephone reviews will be conducted between
appointments (2–4 weeks after each face-to-face
appointment) to review progress and provide additional
support during the 6-month active intervention period
Fig. 1 Trial design for the CAVIAR study showing randomisation arms comparing active versus passive lifestyle intervention in 130 nondiabetic
kidney allograft recipients
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(some appointments could be substituted with
telephone support if wished by patient). Patients will
have their diet reviewed by a dietitian and healthy
eating advice will be given based upon guidelines issued
by Diabetes UK [21]. The guidelines recommend a diet
containing less fat and more fibre, based upon a meal
framework of 50 % carbohydrate, 25 % protein
(meat, fish, beans) and 25 % fibre (fruit and vegetables).
Patients will be advised to keep food diaries to monitor
compliance with initiated changes and will be followed
up by the dietitians prospectively (using face-to-face
appointments and telephone reviews) to monitor
progress and reinforce the advice (in addition to
routine clinic visits).
In addition, a graded exercise programme will be
encouraged to increase physical activity (e.g. endurance
exercise such as walking, jogging, swimming) and an
exercise diary will be encouraged to monitor
compliance. To establish and prospectively monitor
exercise habits we will perform Incremental Shuttle
Walk Tests. Validated surveys to assess physical
capability and activity (Duke Activity Status Index and
GP Physical Activity Questionnaire, respectively) will
be performed at each nurse-led assessment.
The dietitian will be supported by our collaboration
with a senior lecturer and consultant in addiction
psychiatry, who has a recognised expertise in behaviour
change therapy, and will support the behaviour therapy
component of the active intervention arm. The
behaviour change intervention will be developed in
conjunction with the dietitians, and will utilise
NLM tools developed from a Public Health
England manual [22]. Based on the research
evidence summarised above, it will include the
following BCTs:
1. Provide information on the consequences of
suboptimal diet and exercise levels on health in
general
2. Provide specific feedback of personalised
information (body mass index, body fat percentage,
waist/hip ratio) and comparison with the healthy
range
3. Prompt intention formation, i.e. encouraging the
patient to make a resolution to change their diet
or level of exercise
4. Set specific goals around diet, exercise and weight
(see Figs. 2, 3 and 4)
5. Set graded tasks around the achievement of patient
goals
6. Encourage self-monitoring of goals through
food and exercise diaries and other Node-link
maps
7. Regular review of specific behavioural goals, and
reinforcement of progress through praise and
encouragement
8. Review of social support available from personal
network of family and friends, and linking support
to the achievement of specific goals.
Fig. 2 Intervention slide outlining patient dietary goals used to support the behaviour change element of the active lifestyle intervention
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Passive control group. This group will be counselled
about the risks of glucose intolerance and will receive
leaflets outlining lifestyle modification advice. The
leaflets include advice on healthy eating, exercise and
the importance of weight loss. However, there will be
no dietitian referral or focussed exercise and
weight-loss monitoring review and no behaviour
therapy intervention. Follow-up will be at routine clinic
visits only where lifestyle modification advice will be
reinforced as per usual clinical practice.
Fig. 3 Intervention slide outlining patient exercise goals used to support the behaviour change element of the active lifestyle intervention
Fig. 4 Intervention slide outlining patient weight goals used to support the behaviour change element of the active lifestyle intervention
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After 6 months of either intervention, both groups will
undergo a repeat OGTT to assess any change in gly-
caemic status and metabolic physiological parameters. If
any kidney allograft recipient develops PTDM during
the course of the study, then they will be treated as per
protocol (lifestyle modification advice with glucose-
lowering therapy based upon individualised clinical
assessment).
Study outcomes
Primary endpoint
1. Difference in insulin secretion, sensitivity and
disposition index
Secondary endpoints
1. Incidence of PTDM
2. Incidence of impaired glucose tolerance
3. Incidence of impaired fasting glucose
4. Commencement of glucose-lowering therapy
5. Difference in glycated haemoglobin (HbA1c)
6. Change in weight, body mass index, waist/hip ratio,
triceps skin-fold thickness
7. Change in bioimpedance parameters (fluid, fat and
muscle tissue mass and indexes)
8. Change in blood pressure and lipid profile
9. Change in physical activity (Incremental Shuttle
Walk Tests, Duke Activity Status Index and GP
Physical Activity Questionnaire, respectively)
10. Change in psychological wellbeing (using two of
three instrumental tools which have been validated
in kidney transplant populations):
EQ5D – quality of life and health status [23]
Beck Depression Inventory (BDI-II) – specific
tool for depression* [24]
Situational Motivation Scale (SMS) –
specific tool for assessment of situational
motivation [25]
11. Long-term clinical outcomes (patient survival,
allograft survival, cardiac events, weight, etc) via
electronic tagging to the electronic patient records
at University Hospitals Birmingham (via Patient
Registration number) and national registries
(via NHS number)
*Patients will be offered leaflets with the clinical
psychology department’s contact details if self-harm is
reported.
Safety endpoints
1. Change in creatinine
2. Change in proteinuria (urine albumin-creatinine ratio)
Flowchart of investigations
Clinical data
Demographic data will be collected for each individual
participant at the beginning of the study to record base-
line clinical details. Pertinent clinical data (e.g. weight,
waist/hip ratio, triceps skin-fold thickness, blood pressure,
bioimpedance parameters (fluid, fat and muscle mass),
etc.) will be collected at baseline and at follow-up at se-
lected study points as demonstrated in Table 1.
Biochemical data
Biochemical tests, to be done at baseline and follow-up
(see Table 1) will include: plasma total cholesterol, low-
density lipoprotein (LDL) and high-density lipoprotein
(HDL) cholesterol, triglycerides, fasting glucose, urea
and electrolytes, creatinine, full blood count, C-reactive
protein (CRP), HbA1c, insulin and a range of diabetes/
obesity biomarkers via a multiplex immunoassay (includes
C-peptide, ghrelin, GIP, GLP-1, glucagon, leptin, total
PAI-1, resistin, visfatin and adiponectin). The OGTT will
obtain fasting blood samples for glucose in addition to
routine clinic bloods after an overnight 12-h fast. Patients
will then be administered 75 g of glucose (113 mL of
Polycal®) with postprandial samples taken 2 h after glucose
administration. The results of the test will be classified by
current International Consensus recommendations for the
diagnosis of PTDM [10], which mirror guidance in the
general population for the diagnosis of diabetes [26].
Metabolic parameter assessments
Venous blood sampling from both baseline and follow-up
OGTTs will be used to determine changes in insulin
sensitivity, insulin secretion and the disposition index
(interrelationship between both insulin sensitivity and
secretion). The following formulae will be utilised for de-
termination of these parameters of glucose metabolism:
Insulin secretion¼HOMAsec¼Insulin0 3:33= glucose0−3:5ð Þ½ 
Insulin sensitivity¼McAuley0s index¼exp
½2:63−ð0:28  In insulin0=6:945f gÞ
− 0:31  In trigycerides0Þð
Disposition index¼HOMAsecMcAuley0s index¼Insulin0
 3:33 = glucose0−3:5ð Þ½   exp
½2:63−ð0:28  In insulin0=6:945f gÞ
− 0:31  In trigycerides0Þð
Surrogates for insulin sensitivity [27] and disposition
index [28] have previously been validated and reported
in the context of kidney transplantation. In addition to
allowing us to determine the difference between active
versus passive lifestyle intervention, comparison of base-
line and follow-up glucose metabolic parameters will
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provide some insight into underlying pathophysiological
mechanisms that lead to progression of abnormal glucose
metabolism post transplantation.
Electronic data capture
Patients will be consented to electronic data capture of
clinical parameters (e.g. weight, body mass index,
creatinine, etc) from the electronic patient records of
University Hospitals Birmingham at 1, 3 and 5 years post
recruitment (utilising individual unique Patient Registra-
tion number). In addition, clinical outcomes (e.g. patient
survival, allograft survival, hospitalisation, cardiac events,
etc) will be electronically captured from Hospital Epi-
sodes Statistics for the same time points (utilising NHS
number). This will allow long-term data capture without
direct patient involvement and allow us to investigate
the long-term effects of study interventions beyond the
initial study intervention period.
Sample size
The principle parameters being examined in this study
are changes in insulin sensitivity and insulin secretion.
Our power calculation was performed with the assump-
tion of a 20 % dropout rate and on the basis of an
intention-to-treat analysis. We anticipate changes in the
primary outcome measure from 5 % in the control group
and 25 % in the intervention group. These figures are
based on intrasubject variability of 25 % for insulin
secretion and 20 % for insulin sensitivity, as previously
utilised in a different randomised controlled trial in a
post-transplantation setting [29].
Therefore, if we assume 80 % of the control group will
demonstrate a 5 % change in the primary outcome
measure (and 20 % dropouts demonstrate no change),
then the average change in the control group is 4 %.
Similarly, if we assume 80 % of the intervention group
will demonstrate a 25 % change in the primary outcome
measure (and 20 % dropouts demonstrate no change),
then the average change in the intervention group is
20 %.
To detect this difference of 16 % change (assuming
standard deviation of change is 25 %), we calculate that
a total of 130 patients are required (65 per randomised
arm) for 95 % power (assuming a 5 % significance level
and a two-sided test) for a high-powered sample size.
Statistical analysis
Normality of data will be assessed using the Kolmogorov-
Smirnov tests. The paired sample t test and the Wilcoxon
signed rank test, for parametric and nonparametric data,
respectively, will be used to compare the means of
two variables from a single group. Comparison of data
Table 1 Flowchart of study investigations
Investigations Days post recruitment Years post recruitment
0 60 90 120 180 1 3 5
Randomisation Mid-way
point
Post
intervention
Post
intervention
Post
intervention
Post
intervention
Dietitian review with clinical psychology
input (if active arm)
X X X
Standard blood and urine testsa X X X X X
Baseline demographicsb X
Clinical assessmentc X X X
Patient-reported outcomesd X X X
Glucose X X X X X
Insulin X X X
Diabetes/obesity immunoassaye X X X
Triglycerides X X X
Oral glucose tolerance test X X
HbA1c X X X
Electronic capture of clinical outcomesf X X X
aRoutine clinical blood and urine tests include renal function, tacrolimus levels, liver function tests, full blood count, urine albumin-creatinine ratio, etc.
bExtensive baseline data including cause of end-stage kidney disease, dialysis modality, dialysis duration, family history of diabetes, gestational diabetes, hepatitis
C status, etc.
cBlood pressure, waist/hip ratio, weight, height, body mass index, bioimpedance (fluid, fat and muscle mass/index estimation), etc.
dPatient-reported outcomes (physical activity and psychological wellbeing as highlighted above)
eC-peptide, ghrelin, gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1), glucagon, leptin, total plasminogen activator inhibitor-1 (PAI-1), resistin,
visfatin and adiponectin
fLong-term clinical outcomes (patient survival, allograft survival, cardiac events, weight, etc) via electronic tagging to University Hospital Birmingham’s electronic
patient records (via Patient Registration number) and national registries (via NHS number)
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between groups will be made using unpaired Student’s t
tests and the Mann-Whitney test for parametric and non-
parametric data, respectively. Categorical data will be ana-
lysed using Pearson’s or Spearman’s test as appropriate.
We will use Cox proportional hazards regression to
analyse survival outcomes. Additionally, for all primary
and secondary analyses, we will carry out multivariable
analyses using generalised linear models (adjusting for
stratification factors). In this case, we will use the corre-
sponding odds ratio to evaluate the adjusted size of the
differences between proportions, by transforming back
the estimated odds ratio associated with the treatment
group into absolute differences in proportions. If the
results of the analysis of the primary outcome are signifi-
cantly affected, the adjusted effects will be taken as final.
A p value <0.05 will be considered significant in the
statistical analysis.
Withdrawal of subjects
Individual recruits can withdraw at any time for any rea-
son. Should a patient decide to withdraw from the study,
all efforts will be made to report the reason for with-
drawal as thoroughly as possible. Participants who wish
to withdraw from treatment will be asked to confirm
whether they are still willing to provide study-specific
data and samples for scientific laboratory analysis ac-
cording to the trial protocol. In addition, should a pa-
tient withdraw, efforts will be made to obtain follow-up
data with the permission of the patient (e.g. electronic
data capture).
Discussion
Despite the importance of PTDM as a cause of morbid-
ity, mortality, increased cost and patient anxiety, there is
a paucity of randomised controlled trials exploring inter-
ventions that can attenuate the development of diabetes
in a metabolically high-risk cohort like kidney allograft
recipients. While strategies to attenuate the high risk for
developing PTDM (and other cardiometabolic risk fac-
tors) should be actively pursued after solid organ trans-
plantation, we have no evidence that these interventions
are beneficial (either in the short or long term) and this
evidence is extrapolated from the general population.
However, transplant-specific data is important as the
cardiometabolic milieu of kidney transplantation is dif-
ferent from the general population due to immunosup-
pressant side effects, weight gain and fatigue being more
common post transplantation. We should, therefore, be
hesitant to simply translate guidance from general to
kidney transplant recipient cohorts. In addition, the
metabolically high-risk environment after kidney trans-
plantation may justify a more active approach to deliver
lifestyle modification intervention. While lifestyle modi-
fications are recommended as part of existing PTDM
International Consensus recommendations [10], they
lack a clinical evidence base post transplantation and po-
tential efficacy has been translated from outcome data in
the general population. In addition, no recommendation
is made with regards to whether intervention should be
active or passive. Previous work has shown that active
lifestyle intervention (dietitian-led) improved glucose
metabolism in kidney allograft recipients with impaired
glucose metabolism, while by contrast passive lifestyle
intervention (leaflet advice) led to deterioration in glu-
cose metabolism in kidney allograft recipients with
normal glucose metabolism [12]. The limitations of this
study were that it was nonrandomised and comparison
of active versus passive lifestyle intervention was not
performed in a similar cohort of patients. This rando-
mised controlled study will be the first clinical trial to
explore the benefits of active versus passive lifestyle
intervention post kidney transplantation.
One of the great strengths of this study design is the
specialist involvement to support behaviour therapy
change in study recruits to encourage active lifestyle
intervention. This is an important aspect of care as the
key role of cognitive processes in the success or failure
of lifestyle modification is well-documented [30]. From a
transplantation perspective, there is a paucity of data
with regards to the psychological aspects of receiving a
kidney allograft. Evidence suggests that kidney allograft
recipients experience a range of positive and negative
emotions after kidney transplantation including guilt,
fear and gratefulness [31]. Psychological conflicts have
been shown to affect both motivation and behaviour to
undertake lifestyle modification post solid organ trans-
plant recipients [32]. No randomised controlled trial in
kidney transplantation has ever been published evaluat-
ing the efficacy of psychosocial intervention through
behaviour therapy and the potential application of this
study to other domains of post-transplant care (e.g. medi-
cation adherence, anxiety, depression, etc) are significant.
In summary, this randomised controlled trial assessing
the efficacy of a multidisciplinary approach to encourage
lifestyle interventions on glucose metabolism has been
designed to answer unresolved questions in an import-
ant cohort of patients at high risk for developing PTDM.
If the aims of this project are realised, then it will pro-
vide a clinical evidence base to support active lifestyle
interventions as a standard part of the post-transplant
care delivered to all kidney allograft recipients and
address one of the many outstanding research ques-
tions in kidney transplantation. It will also support
the reorganisation of service delivery with multidiscip-
linary care support by allied health professionals to
ensure that patient education through active lifestyle
intervention is actively pursued for kidney allograft
recipients.
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Trial status
Patient recruitment started in August 2015 and at the
time of submission, 48 kidney allograft recipients have
been recruitment and randomised to active or passive
lifestyle intervention. The clinical trial is on target to
complete recruitment by 2017.
Endnotes
In the transplantation literature, post-transplantation
diabetes mellitus (PTDM) has been recommended to re-
place the previous terminology of new-onset diabetes
after transplantation (NODAT). While we have utilised
the up-to-date terminology to reflect this shift in em-
phasis, readers may find some continued publications
citing the older term NODAT in the literature.
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